INTRODUCTION

- Migraine is a common, recurrent, incapacitating disorder characterized by moderate to severe headaches and disabling features, including nausea, vomiting, neurologic symptoms, photophobia, and phonophobia (International Headache Society [IHS] 2013, Starling et al 2015).
- There are 4 phases of a migraine attack, although not all migraine attacks unfold into all 4 phases. These phases include prodrome, development of aura, the headache phase, and postdrome. Combined, all 4 phases can last anywhere between 3 and 5 days (Burgos–Vega et al 2015).
- The pathophysiology of migraines is assumed to involve the activation of trigeminal sensory nerves, which triggers the release of vasoactive neuropeptides including CGRP, neurokinin A, and substance P. CGRP is involved in migraine pathophysiology through nociceptive mechanisms in the trigeminovascular system. CGRP is a vasodilator and is found at higher concentrations during a migraine attack. Vasodilation of dural blood vessels may occur with extravasation of dural plasma, resulting in inflammation (Goadsby et al 2017, Starling et al 2015, Silberstein et al 2012).
- The International Classification of Headache Disorders (ICHD) defines chronic migraine as ≥ 15 headache days per month for > 3 months with the features of migraine headache for at least 8 migraine days per month (MMD). The most common cause of symptoms suggestive of chronic migraine is medication overuse. According to the ICHD, around 50% of patients apparently with chronic migraine revert to an episodic migraine type after drug withdrawal; such patients are in a sense wrongly diagnosed with chronic migraine. In most clinical trials, migraine that is not chronic (ie, with < 15 headache days per month) is considered to be episodic migraine, although the condition is not clearly defined in the ICHD (IHS 2013, Silberstein et al 2008, Starling et al 2015).
- Migraines have a global prevalence of 15 to 18% and are a leading cause of disability worldwide. Chronic migraine is estimated to occur in 2 to 8% of patients with migraine, whereas episodic migraine occurs in more than 90% of patients (Global Burden of Disease Study [GBD] 2016, IHS 2013, Lipton et al 2016, Manack et al 2011).
- Treatments for migraines are divided into acute and preventive therapies. Evidence and reputable guidelines clearly delineate appropriate therapies for episodic migraine treatment and prophylaxis; options stretch across a wide variety of therapeutic classes and are usually oral therapies. For the prevention of migraines, treatment options include oral prophylactic therapies, injectable prophylactic therapies, and neuromodulator devices. Guidelines discourage the overuse of acute headache therapies, including analgesics, triptans, and ergots, which can precipitate medication overuse headache. Additionally, opioids and barbiturates should not be prescribed as they may contribute to the development of chronic daily headache (American Migraine Foundation [AMF] 2017, Edvinsson et al 2017, IHS 2013, Silberstein et al 2008, Silberstein et al 2012, Simpson et al 2016, Starling et al 2015).
  - Oral prophylactic therapies have modest efficacy; however, certain oral therapies may not be appropriate for individual patients due to intolerability or eventual lack of efficacy.
  - Onabotulinumtoxin A (Botox), the first injectable drug approved for the prophylaxis of chronic migraine, has been found to be ineffective for the prophylactic treatment of episodic migraines.
  - Other options include devices which leverage electrical, temperature–altering, or magnetic approaches to treatment (ie, Cefaly, SpringTMS, and gammaCore); these devices are considered to have no significant adverse events known or expected.
- The CGRP pathway is important in pain modulation. Erenumab-aooe is a fully human monoclonal antibody, which potently binds to the CGRP receptor in a competitive and reversible manner with greater selectivity than to other human calcitonin family receptors (eg, calcitonin, amylin, and adrenomedullin). Fremanezumab-vfrm and galcanezumab-gnlm are 2 humanized monoclonal antibodies that target and potently bind the CGRP ligand, in most cases both the α and β isoforms (Dodick et al 2018[b], Edvinsson 2017, Goadsby et al 2017, Silberstein et al 2017, Sun et al 2016, Tepper et al 2017).
- Medispan class: Migraine products – monoclonal antibodies; Calcitonin gene–related peptide (CGRP) receptor antagonists
Table 1. Medications Included Within Class Review

<table>
<thead>
<tr>
<th>Drug</th>
<th>Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimovig (erenumab-aooe)</td>
<td>−</td>
</tr>
<tr>
<td>Ajovy (fremanezumab-vfrm)</td>
<td>−</td>
</tr>
<tr>
<td>Emgality (galcanezumab-gnlm)</td>
<td>−</td>
</tr>
</tbody>
</table>

(Reproduced from Drugs@FDA 2018, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2018)

INDICATIONS

Table 2. Food and Drug Administration Approved Indications

<table>
<thead>
<tr>
<th>Indication</th>
<th>Aimovig (erenumab-aooe)</th>
<th>Ajovy (fremanezumab-vfrm)</th>
<th>Emgality (galcanezumab-gnlm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventive treatment of migraine in adults</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>


- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

CLINICAL Efficacy SUMMARY

- Erenumab-aooe has been studied in approximately 2500 patients across 4 trials in patients with episodic or chronic migraine subtypes and 1 open-label extension (OLE) trial with data from interim analyses in published and unpublished formats.
- Fremanezumab-vfrm has been studied in approximately 2005 patients across 3 trials in patients with episodic or chronic migraine subtypes, with data in published formats. In fremanezumab-vfrm trials, the definition of a headache or migraine day for the primary endpoint required a consecutive 2 hour (episodic) or 4 hour (chronic) duration of pain, compared to other CGRP inhibitor trials which required a duration of ≥ 30 minutes.
- Galcanezumab-gnlm has been studied in approximately 2886 patients across 3 trials in patients with episodic or chronic migraine subtypes and 1 long-term safety trial with unpublished data to 1 year.
- The definition of the primary and secondary endpoints differed in the prevention of episodic and chronic migraine trials. Additional differences included but were not limited to, co-morbid conditions, concomitant medications, a requirement of stable doses of migraine prevention medication (if co-administered) for certain durations, the definition of headache, migraine headache, and migraine day. Some CGRP inhibitor trials allowed patients to receive concomitant preventive migraine medication during treatment. Also, some chronic migraine trials allowed for the inclusion of patients with medication overuse headache.

Episodic migraine

**Erenumab-aooe**

- The STRIVE trial was a 6-month, double-blind (DB), placebo-controlled (PC), multi-center (MC), Phase 3 trial in which 955 patients with episodic migraine were randomized to placebo (n = 319), erenumab-aooe 70 mg (n = 317), or erenumab-aooe 140 mg (n = 319) once monthly. The primary endpoint was the change in mean MMD from baseline to months 4 to 6, which favored treatment with erenumab–aooe 70 mg (mean change vs placebo, −1.4; 95% confidence interval [CI], −1.9 to −0.9; p < 0.001) and erenumab–aooe 140 mg (mean change vs placebo, −1.9; 95% CI, −2.3 to −1.4; p < 0.001). Erenumab–aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 70 mg vs placebo, 16.7%; odds ratio [OR], 2.13; difference for 140 mg vs placebo, 23.4%; OR, 2.81). Erenumab–aooe was also associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference for 70 mg vs placebo, −0.9; difference for 140 mg vs placebo, −1.4) (Goadsby et al 2017).

- The ARISE trial was a 12-week, DB, PC, MC, Phase 3 trial in which 577 patients with episodic migraine were randomized to placebo (n = 291) or erenumab-aooe 70 mg (n = 286) once monthly. The primary endpoint was the change in MMD from baseline to weeks 9 to 12, which favored treatment with erenumab–aooe 70 mg (mean change vs placebo, −1.0; 95% CI, −1.6 to −0.5; p < 0.001). Compared to placebo, erenumab–aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference, 10.2%; OR, 1.59). Erenumab–aooe was also...
The LIBERTY trial was a 12-week, DB, PC, MC, Phase 3b trial in which 246 patients with episodic migraine who failed 2 to 4 prior preventive migraine treatments were randomized to placebo (n = 125) or erenumab-aooe 140 mg (n = 121) once monthly. The primary endpoint was the proportion of patients with ≥ 50% reduction in MMD from baseline to the last 4 weeks of DB treatment (weeks 9 to 12), which erenumab–aooe significantly increased over placebo (difference, 16.6%; OR, 2.73; 95% CI, 1.43 to 5.19; p = 0.002). Compared to placebo, a total of 5.9% more patients treated with erenumab–aooe 140 mg reported a 100% reduction in MMD, or migraine cessation. Erenumab 140 mg/month compared with placebo significantly reduced the MMD (difference, −1.61; 95% CI, −2.70 to −0.52; p = 0.004). Erenumab–aooe was also associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference, −1.73) (Reuter et al 2018[a,b]).

### Fremanezumab-vfrm

The HALO-EM trial was a 12-week, DB, PC, MC, Phase 3 trial in which 875 patients with episodic migraine were randomized to placebo (n = 294), fremanezumab-vfrm 225 mg once monthly (n = 290), or fremanezumab-vfrm 675 mg once quarterly (n = 291). The primary endpoint was the change in mean MMD, which favored treatment with fremanezumab-vfrm 225 mg (mean change vs placebo, −1.5; 95% CI, −2.0 to −0.9; p < 0.001) and fremanezumab-vfrm 675 mg (mean change vs placebo, −1.3; 95% CI, −1.8 to −0.7; p < 0.001). Of note, HALO-EM was powered to detect a 1.6-day difference in the MMD between the fremanezumab-vfrm and placebo groups, but effect sizes resulted in a 1.5-day reduction for the fremanezumab-vfrm monthly dosing group and a 1.3-day reduction for the fremanezumab-vfrm quarterly dosing group. Although the threshold was not reached, a minimal clinically important difference has not been established for this particular outcome. Compared to placebo, greater MMD reductions were also observed in patients who were prescribed fremanezumab-vfrm 225 mg (mean change vs placebo, −1.3) and 675 mg (mean change vs placebo, −1.1) as monotherapy. Fremanezumab-vfrm significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 225 mg vs placebo, 19.8%; OR, 2.36; difference for 675 mg vs placebo, 16.5%; OR, 2.06). Additionally, fremanezumab-vfrm was associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference for 225 mg vs placebo, −1.4; difference for 675 mg vs placebo, −1.3) (Dodick et al 2018[b]).

### Galcanezumab-gnlm

The EVOLVE-1 and EVOLVE-2 trials were 6-month, DB, PC, MC, Phase 3 trials in 858 and 915 patients with episodic migraine, respectively. Patients were randomized to placebo (EVOLVE-1, n = 433; EVOLVE-2, n = 461), galcanezumab-gnlm 120 mg once monthly (EVOLVE-1, n = 213; EVOLVE-2, n = 231), or galcanezumab-gnlm 240 mg once monthly (EVOLVE-1, n = 212; EVOLVE-2, n = 223). Patients in the galcanezumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The EVOLVE-1 trial included a North American population and the EVOLVE-2 trial included a global population. The primary endpoint was the change in mean monthly migraine headache days (MMHD) (Stauffer et al 2018, Skljarevski et al 2018).

In EVOLVE-1, the primary endpoint outcome favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, −1.9; 95% CI, −2.5 to −1.4; p < 0.001) and galcanezumab-gnlm 240 mg (mean change vs placebo, −1.8; 95% CI, −2.3 to −1.2; p < 0.001). Galcanezumab-gnlm significantly increased the proportion of patients achieving ≥ 50% reduction in MMHD (difference for 120 mg vs placebo, 23.7%; OR, 2.64; difference for 240 mg vs placebo, 22.3%; OR, 2.50). Compared to placebo, a total of 9.4% more patients treated with galcanezumab-gnlm 120 mg and 9.4% more treated with galcanezumab-gnlm 240 mg reported a 100% reduction in MMHD, or migraine cessation. Galcanezumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference for 120 mg vs placebo, −1.8; difference for 240 mg vs placebo, −1.6) (Stauffer et al 2018).

In EVOLVE-2, the primary endpoint outcome favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, −2.0; 95% CI, −2.6 to −1.5; p < 0.001) and galcanezumab-gnlm 240 mg (mean change vs placebo, −1.9; 95% CI, −2.4 to −1.4; p < 0.001). Galcanezumab-gnlm significantly increased the proportion of patients achieving ≥ 50% reduction in MMHD (difference for 120 mg vs placebo, 23.0%; OR, 2.54; difference for 240 mg vs placebo, 21.0%; OR, 2.34). Compared to placebo, a total of 5.8% more patients treated with galcanezumab-gnlm 120 mg and 8.1% more treated with galcanezumab-gnlm 240 mg reported migraine cessation. Galcanezumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference for 120 mg vs placebo, −1.8; difference for 240 mg vs placebo, −1.7) (Skljarevski et al 2018).
**Chronic migraine**

**Erenumab-aooe**
- Erenumab-aooe was studied in a 12–week, DB, PC, MC, Phase 2 trial in which 667 patients with chronic migraine were randomized to placebo (n = 286), erenumab–aooe 70 mg (n = 191), or erenumab–aooe 140 mg (n = 190) once monthly. The primary endpoint was the change in MMD from baseline to weeks 9 to 12, which favored treatment with erenumab–aooe 70 mg and erenumab–aooe 140 mg (mean change for both doses vs placebo, −2.5; 95% CI, −3.5 to −1.4; p < 0.0001). Erenumab–aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 70 mg vs placebo, 17%; OR, 2.2; difference for 140 mg vs placebo, 18%; OR, 2.3). Both erenumab–aooe 70 mg (difference, −1.9) and erenumab–aooe 140 mg (difference, −2.6) significantly reduced the mean acute migraine–specific medication days; however, the higher 140 mg dose had a greater reduction numerically over placebo and reductions may be dose–dependent (Tepper et al. 2017).

**Fremanezumab-vfrm**
- Fremanezumab-vfrm was studied in a 12-week, DB, PC, MC, Phase 3 trial, HALO-CM, in which 1130 patients with chronic migraine were randomized to placebo (n = 375), fremanezumab-vfrm 225 mg once monthly (n = 379), or fremanezumab-vfrm 675 mg once quarterly (n = 376). Patients in the fremanezumab-vfrm 225 mg group received a loading dose of 675 mg at the first injection only. The primary endpoint was the change in mean headache days (MHD), which favored treatment with fremanezumab-vfrm 225 mg (mean change vs placebo, −2.1; standard error [SE], ± 0.3; p < 0.001) and fremanezumab-vfrm 675 mg (mean change vs placebo, −1.8; SE, ± 0.3; p < 0.001). Fremanezumab-vfrm significantly increased the proportion of patients achieving ≥ 50% reduction in MHD (difference for 225 mg vs placebo, 22.7%; OR, 2.73; difference for 675 mg vs placebo, 19.5%; OR, 3.13). Additionally, fremanezumab-vfrm was associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference for 225 mg vs placebo, −2.3; difference for 675 mg vs placebo, −1.8) (Silberstein et al. 2017).

**Galcanezumab-gnlm**
- Galcanezumab-gnlm was evaluated in a 12-week, DB, PC, MC, Phase 3 trial, REGAIN, in which 1113 patients with chronic migraine were randomized to placebo (n = 558), galcanezumab-gnlm 120 mg once monthly (n = 278), or galcanezumab-gnlm 240 mg once monthly (n = 277). Patients in the galcanezumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The primary endpoint was the change in MMDH, which favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, −2.1; 95% CI, −2.9 to −1.3; p < 0.001) and galcanezumab-gnlm 240 mg (mean change vs placebo, −1.9; 95% CI, −2.7 to −1.1; p < 0.001). Galcanezumab-gnlm significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 120 mg vs placebo, 12.2%; OR, 2.10; difference for 240 mg vs placebo, 12.1%; OR, 2.10). Compared to placebo, a total of 0.2% more patients treated with galcanezumab-gnlm 120 mg and 0.8% more treated with galcanezumab-gnlm 240 mg reported migraine cessation, this was not statistically different for either dose group. Galcanezumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine–specific medication treatment days (difference for 120 mg vs placebo, −2.5; difference for 240 mg vs placebo, −2.1) (Detke et al. 2018).

**Open-label extensions (OLE) and long-term safety studies**
- One published OLE with data to 1 year and 1 unpublished abstract with data to ≥ 3 years evaluated erenumab-aooe 70 mg (protocol amended to include 140 mg doses) in patients with episodic migraine. Of 472 patients in the parent study, a total of 308 patients completed 1 year of open-label (OL) treatment. For the ≥ 3 year assessment, of the 383 patients enrolled in the OLE, 250 continued into the 140 mg once monthly dosing. At the time of interim analysis, 236 patients remained in the OLE (Amgen [data on file] 2018, Ashina et al. 2017, Ashina et al. 2018).
  - There may be greater improvements with sustained therapy based on a 1-year OLE interim analysis of episodic migraine patients treated with erenumab-aooe 70 mg once monthly. Patients had a mean value of 8.8 MMDs at parent study baseline. After 3 months of treatment in the parent study, the number of MMDs was reduced to 6.3 days (mean change of 2.5 days). After a total of 16 months of treatment, the number of MMDs was reduced to 3.7 days (mean change of 5.1 days). After 64 weeks, a total of 65% (n = 184) of episodic migraine patients achieved a ≥ 50% reduction in MMDs and 26% (n = 73) had achieved a migraine-free status. The most frequently reported adverse events (≥ 4.0 per 100 patient-years) were viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, influenza, and back pain.

- One unpublished OLE evaluated erenumab-aooe 70 mg (protocol amended to include 140 mg doses) with data to 1 year in patients with chronic migraine. A total of 609 patients with chronic migraine enrolled in the OLE. A total of 199 increased their dose from 70 mg to 140 mg by week 28 (Amgen [data on file] 2018, Tepper et al. 2018).
Patients with chronic migraine had a mean value of 18.8 MMDs at parent study baseline. After a total of 1 year of treatment, the number of MMDs was reduced to 8.5 in the erenumab-aooe 70 mg group and 10.5 in the erenumab-aooe 140 mg group. After 1 year of erenumab-aooe 70 mg and 140 mg monthly dosing, a total of 53% and 67% of chronic migraine patients achieved a ≥ 50% reduction in MMDs and 6% and 13% had achieved a migraine-free status, respectively. The most frequently reported adverse events (≥ 2.0 per 100 patient-years) were viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, and arthralgia.

Another unpublished safety study, the CGAJ study, evaluated galcanezumab-gnlm 120 mg (plus 240 mg loading dose) and 240 mg monthly dosing to 1 year in patients with episodic or chronic migraine. At baseline, 80.7% of patients in the galcanezumab-gnlm 120 mg arm and 77.0% in the galcanezumab-gnlm 240 mg arm had episodic migraine. A total of 270 patients who had a history of ≥ 4 MMHDs and ≥ 1 headache-free day/month for the past 3 months continued galcanezumab-gnlm treatment (Eli Lilly and Company [data on file] 2018, Emgality [dossier] 2018, Stauffer et al 2017).

At baseline, patients had a mean value of 9.7 to 11.4 (standard deviation [SD], 6.0 to 6.6) MMHDs. After a total of 1 year of treatment, the number of MMHDs was reduced to 5.6 days in the galcanezumab-gnlm 120 mg group and 6.5 days in the galcanezumab-gnlm 240 mg group. After ≥ 12 consecutive months of treatment, 24.2% of patients treated with galcanezumab-gnlm 120 mg and 34.8% of patients treated with galcanezumab-gnlm 240 mg maintained response. The most frequently reported adverse events (incidence ≥ 15.0%) were injection site pain, nasopharyngitis, and upper respiratory tract infections. One patient discontinued due to suicidal ideation in the galcanezumab-gnlm 120 mg group. There were no overall concerns regarding safety or tolerability.

Caution should be exercised in applying results from extension trials. The OL design may contribute to biased reports. Extension trials may have biased outcomes because those experiencing benefit are included in extension trials; results are useful for reporting trends in treatment. Additionally, there is no comparator to account for placebo effects.

**CLINICAL GUIDELINES**

According to the American Academy of Neurology and American Headache Society (AAN/AHS) – Evidence−based guideline update on the pharmacologic treatment for episodic migraine prevention in adults (Silberstein et al 2012), the following medications are effective preventive treatment options (see Appendix A for a definition of classifications):

- Level A (established efficacy and > 2 Class I trials):
  - Antiepileptic drugs: divalproex sodium, sodium valproate, and topiramate
  - Beta blockers: metoprolol, propranolol, and timolol
  - Triptans (for menstrual related migraine [MRM]): for short−term prophylaxis, frovatriptan

- Level B (probably effective and 1 Class I or 2 Class II trials):
  - Antidepressants: amitriptyline and venlafaxine
  - Beta blockers: atenolol and nadolol
  - Triptans (for MRM): for short−term prophylaxis, naratriptan and zolmitriptan

- Level C (possibly effective and 1 Class II trial):
  - Angiotensin−converting enzyme (ACE) inhibitors: lisinopril
  - Angiotensin II receptor blockers (ARBs): candesartan
  - Alpha agonists: clonidine and guanfacine
  - Antiepileptic drugs: carbamazepine
  - Beta blockers: nebivolol and pindolol
  - Antihistamines: cyproheptadine

The AAN recommends onabotulinumtoxin A as an effective treatment option that should be offered for chronic migraine. However, onabotulinumtoxin A is considered ineffective for the treatment of episodic migraines and should not be offered. There is insufficient evidence to compare the effectiveness of botulinum neurotoxin A with that of oral prophylactic topiramate (Simpson et al 2016).

**SAFETY SUMMARY**

- Fremanezumab-vfrm and galcanezumab-gnlm are contraindicated in patients with serious hypersensitivity to the active ingredient or any of the excipients. Mild to moderate hypersensitivity reactions (eg, rash, pruritus, urticaria) were reported in trials with fremanezumab-vfrm and galcanezumab-gnlm.

- There are no contraindications or warnings and precautions associated with erenumab—aooe.
The CGRP inhibitors generally have a similar incidence of adverse events as placebo. Very few severe adverse events and treatment discontinuations due to adverse events were reported. The most common adverse reactions observed in CGRP inhibitor studies included injection site reactions (all agents) and constipation (erenumab-aooe only).

Caution should be exercised as long-term safety is unknown. CGRP is a vasodilator and is found at higher concentrations during a migraine attack. In the 1-year interim analysis of an OLE study with erenumab-aooe, 2 patients had severe adverse events (an arteriosclerosis event and a myocardial ischemia event), of which 1 was fatal and 1 was confounded by sumatriptan administration. No additional concerns were raised within the OLE at ≥ 3 years, including any cardiovascular events. In a long-term safety study of patients treated with galcanezumab-gnlm for 1 year, 1 patient discontinued due to suicidal ideation in the galcanezumab-gnlm 120 mg group. The long-term implications of prolonged CGRP inhibition are not fully established and safety has not been fully characterized (Amgen [data on file] 2018, Ashina et al 2017, Ashina et al 2018, Eli Lilly and Company [data on file] 2018, Stauffer et al 2017, Tepper et al 2018).

There are no adequate data on the risks associated in patients who are pregnant or nursing, or in adolescent or pediatric populations.

### DOSING AND ADMINISTRATION

#### Table 3. Dosing and Administration

<table>
<thead>
<tr>
<th>Drug</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimovig (erenumab-aooe)</td>
<td>Auto-injector</td>
<td>SC</td>
<td>Once monthly</td>
<td>May be self-administered by patients in the abdomen, thigh, or back of upper arm. Latex-sensitive patients may have an allergic reaction to the needle shield within the white cap and the gray needle cap of the syringe. Must be refrigerated and protected from light until time of use. Once removed from the refrigerator, erenumab-aooe has a limited stability of 7 days.</td>
</tr>
<tr>
<td>Ajovy (fremanezumab-vfrm)</td>
<td>Prefilled syringe</td>
<td>SC</td>
<td>Once monthly or once every 3 months</td>
<td>May be self-administered by patients in the abdomen, thigh, or back of upper arm. The prefilled syringe cap is not made with natural rubber latex. Must be refrigerated and protected from light until time of use. Once removed from the refrigerator, fremanezumab-vfrm has a limited stability of 24 hours.</td>
</tr>
<tr>
<td>Emgality (galcanezumab-gnlm)</td>
<td>Auto-injector</td>
<td>SC</td>
<td>Once monthly</td>
<td>May be self-administered by patients in the abdomen, thigh, back of upper arm or buttocks. The cap is not made with natural rubber latex.</td>
</tr>
</tbody>
</table>
CONCLUSION

- Migraine is a common, recurrent, incapacitating disorder characterized by moderate to severe headaches and disabling features, including nausea, vomiting, neurologic symptoms, photophobia, and phonophobia. Migraines have a spectrum of frequency and severity that can significantly affect the quality of life of patients.

- Guidelines have not been updated to include the CGRP inhibitors. Current evidence-based prophylactic treatment options and guidance are limited for chronic migraine, and oral prophylactic medications prescribed for episodic migraine are often used also for the preventive treatment of chronic migraine. Prophylactic migraine treatment options include oral agents (mainly anti-seizure agents, antidepressants, and beta blockers), injectable agents (onabotulinumtoxin A for chronic subtypes only), or neuromodulation devices for migraine or headache attacks (ie, Cefaly, Spring TMS, gammaCore). Certain oral therapies may not be appropriate for individual patients due to intolerability or eventual lack of efficacy. There is no optimal prophylactic migraine therapy and head-to-head trials are lacking.

- The CGRP inhibitors (erenumab-aooe, fremanezumab-vfrm, and galcanezumab-gnlm) are novel agents developed as alternatives for patients who do not tolerate, or do not have an adequate response to, currently marketed preventive migraine therapies. Like other preventive medications for migraine, the CGRP inhibitors are not likely to render patients migraine-free. Based on 3 to 6 month data, primary endpoint reductions are similar to many oral prophylactic therapies; however, comparisons are limited as endpoints have been inconsistently defined. There are limited analyses and trials examining efficacy in patients who failed ≥ 2 prior preventive therapies; however, available data suggest that these patients may achieve greater reductions in migraine/headache frequency. Further research is warranted.

- There are no head-to-head studies with the CGRP inhibitors and no prophylactic migraine agent is clearly superior to others.
  - Compared to placebo, the CGRP inhibitors consistently demonstrated modest but statistically significant reductions in primary endpoint measures (eg, MMD, MMH, or MMHD) ranging from 1.0 to 2.5 days after 3 to 6 months of treatment. Overall, the odds for a 50% reduction in MM(H)D were approximately 1.6 to 3.1 times higher with the CGRP inhibitors than placebo with numbers-needed to treat (NNTs) ranging from 3 to 10.

- Lack of information during pregnancy and breastfeeding is a consideration as many migraine patients are women of childbearing potential. The unknown risks of monoclonal antibodies and the effects on certain conditions are not fully characterized. Important co-morbid populations that suffer migraines were excluded from trials (eg, anxiety, depression, hypertension, and fibromyalgia), which also limits the generalizability to broader groups. There are no data in adolescents and children. Based on current data, the safety profiles of the CGRP inhibitors are generally mild with the most common adverse effects observed being injection site reactions.

- Overall, the CGRP inhibitors represent another therapy option in the prevention of episodic or chronic migraine. Fremanezumab-vfrm is the only agent in the class that may be administered quarterly, which may fulfill a niche in patients who are non-adherent with treatment. Based on currently available evidence, the mild safety profile of these agents may support a role in a subset of patients unable to tolerate established oral prophylactic therapies. Further long-term study is warranted.

APPENDIX

- Appendix A. AAN levels of evidence classification (Gronseth et al 2011)

| Rating of recommendation | A Established as effective, ineffective, or harmful for the given condition in the specified population |
REFERENCES

- Emgality [dossier]. Indianapolis, IN: Eli Lilly and Company; October 2018.
- Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and safety of erenumab-aooe in episodic migraine patients with 2–4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study [poster]. Presented at the 70th Annual Meeting of the American Academy of Neurology; Los Angeles, CA; April 21 to 27, 2018[b].

Publication Date: January 3, 2019